All news

J&J's 6% slide seen as buying opportunity

Alpha Vantage · CNBC · · AI-summarised by FinFlash

Johnson & Johnson shares fell 6% after an "imperfect" quarter, even though revenue and adjusted earnings per share beat expectations. Strength in the Innovative Medicine segment, led by new psoriasis drug Icotyde, and a robust pipeline offset weakness in medical devices. Analysts see the pullback as a buying opportunity, with a consensus target implying roughly 6% upside.

Read original source

JNJ company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.